Journal article icon

Journal article

[Adjuvant tamoxifen duration: more large-scale randomized evidence is needed]

Abstract:

The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) overview of worldwide evidence has demonstrated that a few years of adjuvant tamoxifen produces a moderate but definite benefit in long-term survival. However, there is major uncertainty regarding the optimal duration of tamoxifen treatment and in particular, as to whether, after a few years on tamoxifen, most women should stop or should continue for several years longer. ATLAS (Adjuvant Tamoxifen: Longer Against Shorter) is a la...

Expand abstract

Actions


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Trial Service Unit
Role:
Author
Journal:
Gan to kagaku ryoho. Cancer and chemotherapy
Volume:
24
Issue:
10
Pages:
1203-1209
Publication date:
1997-08-05
ISSN:
0385-0684
URN:
uuid:f9460046-3e5b-4e05-9aa4-22cf76393f0f
Source identifiers:
75345
Local pid:
pubs:75345

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP